United Therapeutics Co. (NASDAQ:UTHR) Director Sells $797,000.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Down 1.9 %

Shares of UTHR opened at $310.82 on Thursday. The business has a fifty day moving average of $342.26 and a 200 day moving average of $356.31. The company has a market cap of $13.96 billion, a PE ratio of 13.65, a P/E/G ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. During the same period in the previous year, the company earned $4.36 EPS. As a group, research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Wealthfront Advisers LLC boosted its holdings in United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after acquiring an additional 18,313,424 shares during the period. Vanguard Group Inc. lifted its position in shares of United Therapeutics by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock worth $1,567,253,000 after purchasing an additional 32,213 shares during the last quarter. FMR LLC boosted its stake in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock valued at $519,170,000 after purchasing an additional 393,777 shares during the period. Geode Capital Management LLC grew its holdings in shares of United Therapeutics by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company’s stock worth $401,184,000 after purchasing an additional 44,277 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in United Therapeutics by 0.8% in the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company’s stock worth $344,176,000 after buying an additional 7,710 shares during the period. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on UTHR shares. UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.